Diabetic atherosclerosis mouse models

Atherosclerosis

Volumn 191, Issue 2, 2007, Pages 241-249

  Wu, Kenneth K ^a   Huan, Youming ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Atherosclerosis; Diabetes; Insulin resistance; Mice; Mouse model

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ESTROGEN; INSULIN; ROSIGLITAZONE; S 18886; STREPTOZOCIN; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TROGLITAZONE; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; DIET; DIETARY INTAKE; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; ESTROGEN THERAPY; GENETIC ANALYSIS; GENETIC PROCEDURES; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STREPTOZOCIN DIABETES;

ALDEHYDE REDUCTASE; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIETARY CARBOHYDRATES; DIETARY FATS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, LDL; STREPTOZOCIN;

EID: 33947264825     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.08.030     Document Type: Review

References (64)

1. Schoen F. Heart. In: Cotran R.S., Kumar V., and Collins T. (Eds). Robbins Pathologic Basis of Disease. 6th ed. (1999), WB Saunders, Philadelphia 543-599
2. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001) 2486-2497
3. Grundy S.M., Howard B., Smith Jr. S., et al. Prevention conference VI: diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 105 (2002) 2231-2239
4. Howard B.V., Rodriguez B.L., Bennett P.H., et al. Prevention conference VI: diabetes and cardiovascular disease: Writing Group I: epidemiology. Circulation 105 (2002) e132-e137
5. Wendt T., Bucciarelli L., Qu W., et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 4 3 (2002) 228-237
6. Eckel R.H., Wassef M., Chait A., et al. Prevention conference VI: diabetes and cardiovascular disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation 105 (2002) e138-e143
7. Harris M.I., Flegal K.M., Cowie C.C., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1998-1994. Diabetes Care 21 (1998) 518-524
8. Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J 150 (2005) 859-870
9. Ginsberg H.N., and Huang L.S. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 7 (2000) 325-331
10. Vikramadithyan R.K., Hu Y., Noh H.L., et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest 115 9 (2005) 2434-2443
11. Fazio S., and Linton M.F. Mouse models of hyperlipidemia and atherosclerosis. Front Biosci 6 (2001) D515-D525
12. Brondum E., Nilsson H., and Aalkjaer C. Functional abnormalities in isolated arteries from Goto-Kakizaki and streptozotocin-treated diabetic rat models. Horm Metab Res 37 Suppl. 1 (2005) 56-60
13. Portha B., Blondel O., Serradas P., et al. The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin. Diabetes Metab 15 (1989) 61-75
14. Kedar P., and Chakrabarti C.H. Effects of jambolan seed treatment on blood sugar, lipids and urea in streptozotocin induced diabetes in rabbits. Indian J Physiol Pharmacol 27 (1983) 135-140
15. Fletcher J.M., and Bassett J.M. Effects of streptozotocin injection into fetal rabbits on their subsequent growth in utero. Biol Neonate 49 (1986) 51-59
16. Harano Y., Kojima H., Kosugi K., et al. Hyperlipidemia and atherosclerosis in experimental insulinopenic diabetic monkeys. Diabetes Res Clin Pract 16 (1992) 163-173
17. Tsutsumi K., Iwamoto T., Hagi A., and Kohri H. Streptozotocin-induced diabetic cynomolgus monkey is a model of hypertriglyceridemia with low high-density lipoprotein cholesterol. Biol Pharm Bull 21 (1998) 693-697
18. Kunjathoor V.V., Wilson D.L., and LeBoeuf R.C. Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 97 (1996) 1767-1773
19. Otero P., Bonet B., Herrera E., and Rabano A. Development of atherosclerosis in the diabetic BALB/c mice. Prevention with Vitamin E administration. Atherosclerosis 182 (2005) 259-265
20. Reaven P., Merat S., Casanada F., et al. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 17 (1997) 2250-2256
21. Goldberg I.J., Isaacs A., Sehayek E., et al. Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice. Atherosclerosis 172 (2004) 47-53
22. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 (1998) 1025-1031
23. Calkin A.C., Forbes J.M., Smith C.M., et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 25 (2005) 1903-1909
24. Zuccollo A., Shi C., Mastroianni R., et al. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 112 (2005) 3001-3008
25. Tse J., Martin-McNaulty B., Halks-Miller M., et al. Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17 beta-estradiol. Atherosclerosis 144 (1999) 303-313
26. Hayek T., Hussein K., Aviram M., et al. Macrophage foam-cell formation in streptozotocin-induced diabetic mice: stimulatory effect of glucose. Atherosclerosis 183 (2005) 25-33
27. Nestel P., Akihiko Fujii A., and Allen T. The cis-9,trans-11 isomer of conjugated linoleic acid (CLA) lowers plasma triglyceride and raises HDL cholesterol concentrations but does not suppress aortic atherosclerosis in diabetic apoE-deficient mice. Atherosclerosis 189 (2006) 282-287
28. Kako Y., Masse M., Huang L.S., et al. Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. J Lipid Res 43 (2002) 872-877
29. Cheema S.K., and Rashid-Kolvear F. Streptozotocin-induced increase in cholesterol ester transfer protein (CETP) and its reversal by insulin in transgenic mice expressing human CETP. Can J Physiol Pharmacol 81 (2003) 997-1004
30. Fielding C.J., and Fielding P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res 36 (1995) 211-228
31. Renard C.B., Kramer F., Johansson F., et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 114 (2004) 659-668
32. Goldstein B.J. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 90 (2002) 3G-10G
33. Erkelens D.W. Insulin resistance syndrome and type 2 diabetes mellitus. Am J Cardiol 88 (2001) 38J-42J
34. The Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
35. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
36. Kobayashi K., Forte T.M., Taniguchi S., et al. The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 49 (2000) 22-31
37. Zykova S.N., Jenssen T.G., Berdal M., et al. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 49 (2000) 1451-1458
38. Chen H., Charlat O., Tartaglia L.A., et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84 (1996) 491-495
39. Chua Jr. S.C., Chung W.K., Wu-Peng X.S., et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 271 (1996) 994-996
40. Hummel K.P., Dickie M.M., and Coleman D.L. Diabetes, a new mutation in the mouse. Science 153 (1966) 1127-1128
41. Rodgers B.D., Bernier M., and Levine M.A. Endocrine regulation of G-protein subunit production in an animal model of type 2 diabetes mellitus. J Endocrinol 168 (2001) 509-515
42. Nakashima Y., Plump A.S., Raines E.W., et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14 (1994) 133-140
43. Paigen B., Plump A.S., Rubin E.M., et al. The mouse as a model for human cardiovascular disease and hyperlipidemia. Curr Opin Lipidol. 5 (1994) 258-264
44. Plump A.S., Smith J.D., Hayek T., et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71 (1992) 343-353
45. Plump A. Atherosclerosis and the mouse: a decade of experience. Ann. Med. 29 (1997) 193-198
46. Breslow J.L. Mouse models of atherosclerosis. Science 272 (1996) 685-688
47. Wu K.K., Wu T., Chin J., et al. Leptin receptor deficiency accelerates atherosclerosis in ApoE knockout mice and is suppressed by fenofibrate. Circulation 108 17 (2003) (Suppl. IV-107)
48. Wu K.K., Wu T.J., Chin J., et al. Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. Atherosclerosis 181 (2005) 251-259
49. Wendt T., Harja E., Bucciarelli L., et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 185 (2006) 70-77
50. Hasty A.H., Shimano H., Osuga J., et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 276 (2001) 37402-37408
51. Goldberg I.J. Why does diabetes increase atherosclerosis? I don't know!. J Clin Invest 114 (2004) 613-615
52. Gruen M.L., Saraswathi V., Nuotio-Antar A.M., et al. Plasma insulin levels predict atherosclerotic lesion burden in obese hyperlipidemic mice. Atherosclerosis 186 (2006) 54-64
53. Ragolia L., Palaia T., Hall C.E., et al. Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice. J Biol Chem 280 (2005) 29946-29955
54. Federici M., Hribal M.L., Menghini R., et al. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115 (2005) 3494-3505
55. Lu H., Raptis M., Black E., et al. Influence of diabetes on the exacerbation of an inflammatory response in cardiovascular tissue. Endocrinology 145 (2004) 4934-4939
56. Han S., Liang C.P., DeVries-Seimon T., et al. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab 3 (2006) 257-266
57. Lyngdorf L.G., Gregersen S., Daugherty A., and Falk E. Paradoxical reduction of atherosclerosis in apoE-deficient mice with obesity-related type 2 diabetes. Cardiovasc Res 59 (2003) 854-862
58. Nishina P.M., Naggert J.K., Verstuyft J., and Paigen B. Atherosclerosis in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. Metabolism 43 (1994) 554-558
59. Schreyer S.A., Wilson D.L., and LeBoeuf R.C. C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis. Atherosclerosis 136 (1998) 17-24
60. Molnar J., Yu S., MzhaviaN, et al. Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. Circ Res 96 (2005) 1178-1184
61. Collins A.R., Meehan W.P., Kintscher U., et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 365-371
62. Schreyer S.A., Vick C., Lystig T.C., et al. LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice. Am J Physiol Endocrinol Metab 282 (2002) E207-E214
63. Phillips J.W., Barringhaus K.G., Sanders J.M., et al. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation 108 (2003) 1994-1999
64. Cefalu W.T., Wang Z.Q., Schneider D.J., et al. Effects of insulin sensitizers on plaque vulnerability associated with elevated lipid content in atheroma in ApoE-knockout mice. Acta Diabetol 41 (2004) 25-31